Background-Sex differences were observed with regard to warfarin treatment in patients with atrial fibrillation, with women having a higher risk of stroke compared with men. We aimed to compare sex differences in use, safety, and effectiveness of dabigatran. Methods and Results-We conducted a population-based cohort study of patients with atrial fibrillation using administrative data in Quebec, Canada, 1999 to 2013. Men and women who filled a prescription for dabigatran (110 and 150 mg bid) were compared with matched warfarin users with respect to their rates of stroke, bleeding, and myocardial infarction events, using propensity score analysis. The cohort comprised 31 786 women (50.4%) and 31 324 men (49.6%). Women had a higher baseline stroke risk and lower baseline bleeding risk compared with men. Women filled more prescriptions for the lower dabigatran dose compared with men (adjusted OR, 1.35; 95% confidence interval, 1.24-1.48). In multivariable analyses adjusted for propensity scores, dabigatran use was associated with a lower risk of bleeding compared with warfarin in men (P for interaction=0.008). Dabigatran was associated with a trend toward lower risk of stroke in women treated with the 150-mg dose (HR, 0.79; 95% confidence interval, 0.56-1.04), but was not associated with a difference in the risk of myocardial infarction compared with warfarin in either sex. Conclusions-In real-life practice, women are more frequently treated with low-dose dabigatran, yet a trend toward lower stroke rates in women taking high-dose dabigatran was observed. Men benefit from lower bleeding rates with dabigatran compared with warfarin. (Circ Cardiovasc Qual Outcomes. 2015;8:593-599.
W omen with atrial fibrillation (AF), especially those aged ≥75 years, have a higher risk of stroke compared with men, regardless of their risk profile and warfarin treatment. [1] [2] [3] [4] [5] [6] [7] [8] In fact, female sex has been incorporated into several stroke risk stratification schemes used to select patients with AF for anticoagulation. 5, 7, 9 The management of stroke prevention in patients with AF is currently undergoing significant changes with the approval of new oral anticoagulants (NOACs) that have been tested and found to be efficacious in large randomized clinical trials when compared with warfarin. [10] [11] [12] Dabigatran etexilate (hereafter referred to as dabigatran), an oral direct thrombin inhibitor, was the first NOAC approved for use in both the United States and Canada in October 2010. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study, dabigatran given as 150 mg twice daily, was more effective in terms of stroke prevention than warfarin, whereas the 110mg dose demonstrated a lower risk of bleeding. 10 However, in the RE-LY trial, there were fewer females enrolled than male (37%), which raises the question as to whether results obtained in a randomized clinical trial of mainly men can be generalized and applicable to women.
In a study assessing sex differences in the pharmacokinetic and pharmacodynamic profiles of the 150 mg bid dabigatran dose in 18 women and 18 men (≥65 years), the results demonstrated a trend toward increased dabigatran plasma concentrations in women compared with men. 13 Also, in an exposure response analysis from the RE-LY trial, plasma concentrations of dabigatran in female subjects were ≈30% higher than in male subjects. Although the authors conclude that the risks of major bleeding and ischemic stroke were related to trough concentrations of dabigatran, they did not mention sex differences in the association with the outcomes. 14 The overall lack of sex-based analysis in studies conducted to determine the safety and effectiveness of dabigatran in comparison with warfarin leaves a void for unanswered questions about the safety and effectiveness of dabigatran in these subpopulations. [15] [16] [17] [18] [19] Therefore, in this population-based study we aimed to compare sex differences in utilization patterns of dabigatran, and to investigate whether dabigatran has a differential effect in men and women, with regard to stroke, bleeding, and myocardial infarction (MI).
Methods

Study Population and Data Sources
We conducted a population-based cohort study using administrative data. Cohort identification started from inpatient coding for an AF diagnosis. Participants were Quebec residents, discharged alive from hospitalization with a primary diagnosis of AF or a major comorbid diagnosis (secondary diagnosis) of AF (International Classification of Diseases Ninth/Tenth Revision, code 427.3, 427.31, or 427.32 /I48), between January 1, 1999 and March 31, 2013. For patients with >1 eligible admission with an AF diagnosis, the date of the first AF diagnosis was the index AF hospitalization date. The median-positive predicted value of International Classification of Diseases Ninth Revision codes for AF was previously reported to be 89% 20 and recently reported to be 95.7%. 21 We linked the provincial hospital discharge database (Maintenance et Exploitation des Données pour l'Étude de la Clientèle Hospitalière-Med-Echo) to the provincial physician and prescription claims database (la Régie de l'assurance maladie du Quebec). Quebec prescription claims database has been previously determined to be a reliable source of filled medication prescriptions. 22 We used the hospital discharge database to obtain information on patients' characteristics such as comorbidities, and to calculate the CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke or transient ischemic attack (TIA), vascular disease, age 65-74 years, and female sex) and the modified HAS-BLED score (hypertension, abnormal renal function, abnormal liver function, history of stroke, history of bleeding, age ≥65 years, and drug therapy [antiplatelet agents and nonsteroidal anti-inflammatory drugs], not including high international normalized ratio, and alcohol intake). 9,23-25
Dabigatran and Warfarin Users
We identified patients treated with dabigatran as patients who had a filled prescription for dabigatran at any point after index AF hospitalization. Dabigatran doses were identified by the drug identification numbers, and the prescription claims database provided quantity and days of supply information. In this study, we excluded 12 women and 6 men who filled a prescription for dabigatran 75 mg bid.
We then created a comparable warfarin control group by matching dabigatran users to warfarin users, aiming to have a 1:3 ratio, respectively (randomly selected, without replacement). Attempting to avoid cohort effect bias, variation in follow-up length, and to have comparable burden of AF disease between dabigatran and warfarin users, we matched the warfarin control users to the dabigatran users according to 2 dates: (1) date of first dabigatran prescription-for each dabigatran user, the date of first filled dabigatran prescription was matched to a specific warfarin prescription date among warfarin users (±30 days) and (2) year of index AF hospitalization. Patients were considered to be in the warfarin control group only if they were matched to a dabigatran user on both dates, and did not have a record for a filled prescription for dabigatran.
Among dabigatran users, patients were not excluded on the basis of previous warfarin use, to represent real-world practice, in which dabigatran users may have previously used warfarin. Therefore, our cohort included both naive users (patients who did not use warfarin before dabigatran) and prevalent users (patients who were switched from warfarin to dabigatran). The group of warfarin users also consisted of naive and chronic users.
CHA 2 DS 2 -VASc and the modified HAS-BLED scores were determined at the date of first dabigatran-filled prescription or at the matched warfarin prescription date for warfarin users. To identify baseline comorbidities, we used the International Classification of Diseases Ninth/Tenth Revision codes in the most recent hospitalization before the first prescription of dabigatran or matched warfarin prescription date. The use of other medications was reported according to prescriptions filled within 30 days before the date of dabigatran or matched warfarin prescription.
Outcomes
Cohort follow-up started on the date of first prescription filled for dabigatran or matched warfarin prescription. As a first step, we compared dabigatran dose use between men and women. Then, the main outcomes of interest were first hospital admission or emergency room visit for stroke/TIA, or bleeding events, or first hospital admission for MI. Stroke was defined as ischemic cerebrovascular disease, with the inclusion of TIA and retinal infarct. Bleeding events included intracranial hemorrhage, gastrointestinal hemorrhage, and other hemorrhage. Diagnosis codes for all outcomes are described in Data Supplement 1. The criteria to end a patient's follow-up were a first diagnosis of stroke/TIA, bleeding or MI events, death, or end of study period. As a sensitivity analysis, we excluded patients with TIA and retinal infarct from our definition of stroke.
Statistical Analysis
Descriptive statistics were used to compare demographic characteristics, comorbidities, and pattern of dabigatran and warfarin usage between men and women. Continuous variables are presented as mean±SD and dichotomous variables are presented as percentage. Logistic regression was used to determine adjusted odds ratios of dabigatran dose prescription (110 and 150 mg) in women compared with men.
Incidence rates of outcomes were calculated as the number of events per 100 person-years of follow-up and were reported in women and men separately. To eliminate concerns about mortality as a competing risk, we compared the median times to the different outcomes, including mortality.
To further account for differences in baseline characteristics and possible confounding by indication, we calculated 2 sets of propensity scores (ie, the predicted probability that a patient would be a user of dabigatran or warfarin, given baseline covariates): (1) for patients who filled a prescription for the 110 mg bid dose of dabigatran (versus warfarin users) and (2) for patients who filled a prescription for
WHAT IS KNOWN
• The efficacy and safety of dabigatran was investigated in the clinical trial setting but the low enrollment of women (37%) precludes sex-specific conclusions.
WHAT THE STUDY ADDS
• In everyday practice, women with atrial fibrillation are mainly treated with the dabigatran 110 mg twice daily dose; however, they tend to gain more stroke protection with the higher dabigatran dose.
• Men using dabigatran benefit from lower bleeding rates compared with warfarin.
• Neither dabigatran dose was associated with a higher risk of myocardial infarction compared with warfarin in men or women. the 150 mg bid dose of dabigatran (versus warfarin users). The propensity scores were calculated for men and women separately (ie, 2 sets of propensity scores for each sex). The propensity scores were defined by variables that might be associated with the prescription of dabigatran or warfarin. The scores were built with the following covariates: age at dabigatran/matched warfarin prescription, comorbidities associated with CHA 2 DS 2 -VASc score and modified HAS-BLED score (hypertension, acute or chronic kidney disease, liver disease, a history of stroke or TIA, history of bleeding, congestive heart failure, diabetes mellitus, and vascular disease), the use of acetylsalicylic acid, nonsteroidal anti-inflammatory drugs and clopidogrel. In addition, we calculated P values for interactions between dabigatran treatment and sex. For the purpose of these analyses, we calculated separate sets of propensity scores, including both men and women.
To account for differences in follow-up time and to adjust for the effects of potential confounders, we then conducted multivariable analyses by using a Cox proportional hazards regression model, adjusting for the propensity score, valvular disease, chronic obstructive pulmonary disease, type of AF diagnosis (principal or secondary), and the use of other medications (sotalol, amiodarone, other antiarrhythmics, β-blockers, diltiazem, verapamil, digoxin, angiotensin-converting enzyme [ACE] inhibitors, and angiotensin receptor blockers). These variables were not included in the propensity score calculations. The Cox proportional hazards regression models were conducted for all dabigatran users, and in subgroups of 110 and 150 mg bid doses compared with warfarin treatment, in men and women separately. We considered dabigatran or warfarin use as a time-fixed binary variable, where we assumed that patients who were prescribed with the drugs remained on the same prescription throughout the follow-up period.
Statistical analyses were performed using the SAS (version 9.2) statistical software package (SAS Institute Inc, Cary, NC) and the IBM SPSS Statistics software (version 20) . P values for incidence rates were calculated using the WinPepi program.
All statistical tests were 2 sided. P values of <0.05 were considered to be statistically significant. The study received institutional review board approval from McGill University (study number A05-M79-08B).
Results
We randomly matched 15 918 dabigatran users with 47 192 warfarin users (15 682 had 3 matches, 56 had 2 matches, 34 had 1 match, and 146 dabigatran users did not have warfarin users match).
Baseline Characteristics
The cohort was comprised 31 786 women (50.4%) and 31 324 men (49.6%), with a median follow-up of 1.3 years (ranged 0-3.2 years). In general, women were older, and had lower burden of comorbidities compared with men, with the exception of hypertension, valvular heart disease, and a history of stroke, which were more prevalent among women compared with men (Table 1) .
In both sexes, patients who filled a prescription for the 150 mg bid dose were younger, and had less comorbidities compared with patients who filled the 110 mg bid dose and warfarin users (Data Supplement 2). About 35% of men and 30% of women who used dabigatran were warfarin naive.
Mean CHA 2 DS 2 -VASc score was higher in women compared with men (3.9±1.3 versus 2.6±1.4; P<0.001). However, baseline bleeding risk (modified HAS-BLED score) was lower in women compared with men (Table 1) .
Utilization Patterns of Dabigatran by Sex
Similar proportion of men filled a prescription for the dabigatran 110 mg bid dose (48.2%) and 150 mg bid dose (51.8%), whereas most women (64.8%) filled the lower dabigatran does.
Once the population was further stratified by age (younger age group: <75 years; older age group: ≥75 years), we observed that in both age groups, a higher proportion of women filled a prescription for the 110 mg bid dose, compared with men (22.8% versus 18.5% and 83.5% versus 76.0%; P<0.001 in the younger and older groups, respectively).
In a multivariate analysis adjusted for age, baseline comorbidities and treatment with other medications, women tended to fill more prescriptions for the lower dabigatran dose compared with men (adjusted OR, 1.35; 95% confidence interval [CI], 1.24-1.48). Other predictors of dabigatran use are presented in Data Supplement 3.
Sex Differences in Crude Rates of Stroke, Bleeding, and MI
Among patients who filled a prescription for warfarin, compared with men, women had a higher crude stroke incidence (2.95 versus 2.43 per 100 person-years; P<0.001) and lower crude bleeding incidence (6.56 versus 8.43 per 100 personyears; P<0.001; Table 2 ). No sex differences were observed in crude incidence stroke in both dabigatran doses. Nevertheless, in patient treated with dabigatran 110-mg dose, women had lower crude rates of bleeding, and among patients who were treated with the 150 mg, women had lower crude rates of MI compared with men ( Table 2 ).
The median time to mortality was later than all other outcomes. Therefore, we think that mortality poses less of a significant competing risk than anticipated in our analysis.
Multivariable Analyses
In multivariable Cox regression analyses adjusted for the relevant propensity scores, comorbidities, and filled prescriptions, dabigatran was not associated with differences in the risks of stroke or MI compared with warfarin users, in both sexes, regardless of the dabigatran dose ( Figure A and C) . Excluding TIA and retinal infarct from the definition of stroke did not change the risk of stroke in the 110-mg dose; however, it did strengthen the trend for women having a lower risk for stroke with dabigatran 150 mg compared with warfarin (HR, 0.72; 95% CI, 0.52-0.99; Data Supplement 4).
In men, dabigatran use was associated with lower rates of bleeding, at both doses (HR, 0.87; 95% CI, 0.77-0.98 for the 110-mg dose; HR, 0.73; 95% CI, 0.64-0.84 for the 150-mg dose; Figure B ). This association was not observed in women in the lower dabigatran dose, but was on the edge of statistical significance in the higher dose (HR, 0.85; 95% CI, 0.71-1.01; Figure B ). The P value for the interaction term between dabigatran use (110 or 150 dose compared with warfarin) and sex was statistically significant (P=0.008), for the outcome of bleeding.
Discussion
In this contemporary population study, based on everyday practice, we found different utilization patterns of dabigatran among men and women, with women filling more prescriptions for the lower dabigatran dose compared with men. In addition, we found that dabigatran use was associated with lower bleeding rates than with warfarin use, however, this was observed mainly in men. We also observed a trend for women to have a lower incidence of stroke when prescribed dabigatran 150 mg twice daily compared with warfarin.
Sex represents an important modifier of the cardiovascular system and should be recognized as an important factor in both basic science and clinical research. To date, there is a scarcity of information related to sex-specific differences in the effectiveness and safety of cardiovascular treatment, partly because women are not well represented in clinical trials. In addition, few clinical trials have been designed to analyze sex-specific differences in effect and adverse drug reactions of new drugs. [26] [27] [28] Therefore, randomized clinical trials are underpowered to detect true differences for drug effects in women. To optimize patient treatment outcomes, effort must be made to elucidate more information about sex differences in exposures, effectiveness, and safety of new treatments. 29 Although Canadian guidelines do not indicate sex-specific recommendations with regard to dabigatran dose, the patterns of dose prescription in practice in Quebec are apparent: regardless of age or the presence of baseline comorbidities, women have 35% higher chances to be prescribed a lower dabigatran dose compared with men, although women have higher baseline risk for stroke. The reason for this difference is unclear. It is possible, that clinicians perceive women as frailer patients than men, so they tend to be more concerned about safety and, therefore, prescribe women with a lower dose of dabigatran, compromising efficacy. Similar patterns of sex differences in dose use rates of dabigatran were observed in a Danish population-based cohort of patients with low risk for stroke; among the 110-mg dabigatran dose users, 53% were women, whereas among the 150-mg dose users, only 38.5% were women. 17 Further studies are needed to investigate the rationale for differential prescription patterns between men and women.
In this study, dabigatran use was not associated with a difference in stroke risk compared with warfarin use in both sexes and doses; however, there was a trend toward lower stroke risk in women taking the higher dabigatran dose. It is possible that in the real-world setting, women may benefit more from being treated with dabigatran 150 mg in terms of stroke reduction compared with men, because of their higher baseline risk for stroke. However, in practice we found that women are more commonly treated with the lower noninferior 110-mg dose, potentially minimizing our ability to find a difference by sex. This pattern should be clarified in subsequent studies, where women are being treated with the higher dabigatran dose more frequently. Despite the lower baseline bleeding risk of women compared with men, only the men in our study had lower risk of bleeding when both doses of dabigatran were compared with warfarin. Similarly, in a sub analysis of the RE-LY trial, bleeding rates were lower in men using the 110-mg dabigatran dose, 15 and in a systematic review and meta-analysis of randomized trials of NOACs for acute and extended venous thromboembolism treatment, the authors found that men have less bleeding complications than women (relative risk, 0.79; 95% CI, 0.64-0.97). 30 Therefore, results obtained to date suggest that men fair better on NOAC with regard to bleeding, compare to women.
The increased risk of bleeding in women was already described previously in the Canadian Registry of Atrial Fibrillaion (CARAF) study, where women on warfarin were 3.35× more likely to experience major bleeding compared with men, 31 and in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials, where women were more susceptible to anticoagulant-related bleeding. 4 Female sex has also been associated to increase bleeding risk in other clinical settings and other antithrombotic agents. [32] [33] [34] The reason for the sex difference in the risk of bleeding is unclear. With regard to dabigatran, it is possible that women have increased dabigatran plasma concentrations compared with men, possibly because of lower body weight on average, or lower creatinine clearance. These higher concentrations may subsequently translate to higher risk of bleeding. Another potential explanation for the higher bleeding rates in women may be related to sex-specific differences in the coagulation and vascular systems, speculated to be influenced by sex hormones. 35 Further research is required to determine what mediates the excess risk of bleeding in women taking anticoagulation treatment.
Another interesting finding in the bleeding analysis was that the bleeding rates of the 150-mg dabigatran dose were lower than the bleeding rates of the 110-mg dabigatran dose. As given in Table 1 , according to the modified HAS-BLED score the patients treated with dabigatran 110 mg have higher baseline risk for bleeding compared with the patients treated with the 150-mg dose (men: mean HAS-BLED 2.6 and 2.1, respectively). Therefore, it is possible that clinicians tailor the dabigatran dose according to their safety concerns, that is, patients who are at higher risk for bleeding are prescribed the lower dose of dabigatran. Thus, it is possible that the initial higher bleeding risk translated into higher bleeding rates independent of the dabigatran dose and that our adjustment in the multivariate analyses was incomplete. Still, it is important to notice that in men both doses of dabigatran sustained lower rates of bleeding when compared with warfarin, whereas in women, this effect was not seen with either dabigatran doses.
A meta-analysis of randomized noninferiority trials concluded that dabigatran was associated with an increased risk of MI when tested against different controls. 36 The observed increased risk in MI was initially thought to be because of the protective effect of warfarin, 37 however, later reports demonstrated that the increased risk of MI among patients treated with NOACs is probably because of a class effect of NOAC, and not because of protective effect of warfarin. 38, 39 In the multivariate analysis of the current Quebec cohort, we did not find any association between dabigatran use and increased MI rates in the population level. This lack of association may be related to the real-world practice nature of our study, in which, physicians have different consideration for choosing the best fitted treatment for a patient. Indeed, in the Food and Drug Administration report of the Medicare population, there were also no differences in the risk of MI between dabigatran and warfarin users. 40 Although both our study and the Food and Drug Administration report used propensity score matching, well balancing the comorbidities between the dabigatran and warfarin treatment, it is still possible that residual confounding was presented from unmeasured factors. Therefore, further studies focusing on MI outcome should address this possible association found in clinical trials but not in realworld studies.
There are several limitations to our study. The main limitation of our study is that the median follow-up was 1.3 years. It is possible that because of the short follow-up, outcomes risks were underestimated, whereas with longer use, risk may increase. Thus, the inference of risk reported in this study should be limited to the context of 1-year risk after dabigatran initiation. Second, derived from administrative databases, our observational study does not contain information on some important clinical factors, such as AF burden (subtypes and severity of AF), body mass index, international normalized ratio, and time in therapeutic range for warfarin users. Therefore, we still cannot rule out residual confounding from unknown or unmeasured confounders. In addition, although we attempted to minimize confounding by indication by using propensity score analyses, it is still possible that this method did not adequately compensate the potential bias.
Finally, it is also important to notice that the inference of our study would only apply for the patients with AF in the inpatients setting, which consists of the majority of patients with AF. 41 Despite these limitations, the results of this study are driven from a population-based study, and provide novel evidence for possible sex differences in the safety of dabigatran versus warfarin in the population level.
To conclude, we found that sex differences exist in dose use of dabigatran, and that dabigatran safety may differ between men and women, with men having more benefits from dabigatran treatment by having less bleeding events compared with warfarin. The results obtained from this study contribute to the paucity of data available about the clinical impact of sexrelated safety difference.
Sources of Funding
Financial support for this study was provided by an operating grant from the Canadian Institutes of Health Research (grant number MOP-84304). No relationships with industry.
Disclosures
None.
